Ulcerative colitis

Stress and psychological distress are common in people with IBD and may influence symptoms and inflammation. This trial tests whether an 8‑week MBSR program can improve psychological wellbeing and whether those benefits...

Malnutrition and growth failure at diagnosis are common in children with IBD—especially Crohn’s—and can indicate higher inflammatory burden. Monitoring and addressing nutrition and growth is important because most...

This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...

The study suggests a hidden, early molecular defect that leaves intestinal cells primed to die even during clinical remission, which could help explain why flares recur. Measuring these molecular signals might eventually...

Intestinal barrier dysfunction is a likely driver of inflammation and flares in ulcerative colitis, so therapies that restore barrier integrity could help reduce disease activity and recurrence. This review highlights...

The study suggests shared MHC/HLA genetic variants link ulcerative colitis and gastric cancer risk in East Asians, highlighting potential common immune-related susceptibility that could inform research on disease...

If pre‑treatment biopsy features predict response to ustekinumab, clinicians might better select which UC patients are likely to benefit, potentially avoiding ineffective therapy for some and speeding effective treatment...

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Biomedical Signal...

People with IBD often worry whether their disease affects fertility or embryo health. This study directly looks at embryo chromosomal normality during IVF and found similar euploidy rates in patients with and without...

The study provides real-world data on ozanimod effectiveness, safety, and how prior biologic exposure (notably vedolizumab) may affect treatment persistence—information relevant for treatment planning in UC.

New colon-targeted formulations aim to concentrate treatment where inflammation is in ulcerative colitis, which could increase benefit and reduce systemic side effects. Formulation research like this is an early step...

The work links climate and sociodemographic context to IBD burden in tropical regions, which can influence diagnostic recognition, resource needs, and research priorities for communities where IBD is rising.

Automated, quantitative analysis of pathology slides could reduce variability in histological scoring and help track histological healing — a growing therapeutic target in ulcerative colitis.

Researchers are studying a parasite-derived protein (Fh15) that may reduce neutrophil-driven inflammation in sepsis and ulcerative colitis models; this could point toward new anti-inflammatory drug approaches in the...

Researchers found that nearly all people with UC have high-titer autoantibodies to the epithelial integrin αvβ6 that can precede disease and associate with worse outcomes. Understanding whether and how these antibodies...

The study targets REV-ERBα, a regulator of TH17 cells that contribute to Crohn’s disease and ulcerative colitis, so its findings could identify new molecular pathways to target for IBD therapies.

The project targets patients with refractory IBD who lack effective options; a new allogeneic stromal cell therapy could expand treatment choices for people who fail multiple drugs. The work focuses on immune pathways...

This project could introduce a novel, microbiome-targeted oral therapy for Crohn’s disease if the Phase II trial confirms safety and clinical benefit; that matters because many patients need new options when current...

Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response...

This project aims to understand how gut-adapted eosinophils support immune homeostasis or drive pathology in conditions that include IBD and eosinophilic GI disorders, with the goal of enabling more precise...

If intestinal stem cells retain an inflammatory “memory,” that could help explain why some people with IBD have persistent barrier problems and repeated flares despite therapy. Discovering durable molecular changes in...

This project aims to develop a new anti-inflammatory therapy targeting TREM-1 on macrophages, a pathway implicated in IBD. If successful, the approach could offer an alternative for patients who do not respond to current...

A new single-cell analysis tool may help researchers and clinicians studying IBD (here shown for ulcerative colitis) to detect and interpret changes in cell–cell signaling that accompany disease or treatment response.

Patients with IBD often have joint and skin comorbidities that drive symptoms and treatment choices.

This study reports a non-invasive fluorescence probe that detects a reactive nitrogen species (peroxynitrite) linked to intestinal inflammation and shows signal changes in cells, animal models, and mouse feces — a...

Early-stage research suggests a specific probiotic strain may reduce inflammation and alter the gut microbiome and immune-related proteins in an animal model of ulcerative colitis, which could point to future therapeutic...

A drug (flucytosine) caused colitis that looked like an ulcerative colitis flare. Mistaking medication-induced colitis for IBD activity could lead to unnecessary changes in immunosuppressive treatment.

Genetic evidence for causal links between other diseases (for example asthma or multiple sclerosis) and IBD can help researchers prioritize biological pathways and potential therapeutic targets, and may explain why some...

Based on the title and source metadata, this appears to be a patient education related to Ulcerative colitis, Inflammatory bowel disease, and Procedures and surgery. The original article is from Inflammatory Bowel...

This study provides real‑world data on how long biologic‑experienced UC patients stay on ustekinumab, which helps patients and clinicians set expectations about drug persistence and factors that might influence stopping...

This study describes a new microbiome-engineering approach that reduced inflammation in mouse colitis models by sequestering cysteine and altering T cell behavior. If followed up, it could point to novel future therapies...

Because PG is linked to IBD and can be triggered by surgery, a perioperative immunosuppressive approach reported here may be relevant to patients with IBD who have had prior PG or are planning reconstructive surgery.

The study suggests that a simple, multidomain functional measure (intrinsic capacity) is linked to later IBD risk and that combining it with genetic risk may better identify people at higher risk—especially for Crohn’s...

For people with ulcerative colitis needing restorative surgery, the choice between robotic and laparoscopic IPAA may affect short-term surgical outcomes and recovery.

This preclinical study suggests a heat‑killed form of Lactobacillus acidophilus LA‑5 reduced inflammation, oxidative stress, and markers of regulated cell death in a mouse model of ulcerative colitis — with effects...

For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...

Patients who lose response to standard upadacitinib dosing may have a practical option—dose re‑escalation—that could improve symptoms and reduce steroid needs according to a small retrospective cohort summarized here.

If blood bile acid patterns are reproducibly different in IBD and track with disease activity, they could become noninvasive biomarkers to help diagnose IBD or monitor flares. That would be useful for patients and...

Macrophage behavior and metabolic reprogramming help drive inflammation or repair in ulcerative colitis, so understanding these processes could point to new therapies. The review links lab methods and ongoing clinical...

This study describes a novel colon-targeted microgel delivery system carrying an anti-inflammatory natural compound that, in a mouse model, reduced colitis signs and altered gut bacteria — a potential new strategy for...

Diet is a modifiable factor that could influence IBD risk through effects on the gut microbiome and immune pathways.

This registry study shows many people with IBD in Kazakhstan had clinically active disease at enrollment and identifies factors linked with active UC and CD. It highlights potential gaps in disease control and...

Persistent fatigue is a common disabling symptom in IBD even during remission; a structured adapted physical activity program could offer a non-drug way to improve daily functioning if the trial shows benefit.

Long-term, real-world safety data help patients and clinicians understand risks — especially serious infections — when a newer ulcerative colitis drug is used in routine practice. This registry entry shows Pfizer is...

The study links a common dietary fiber (green banana resistant starch) to microbiota changes and production of propionate that protect the colonic barrier and reduce inflammation in a mouse model of ulcerative colitis.

This study proposes specific plant compounds and molecular pathways that could be relevant to ulcerative colitis, which may guide future lab research and drug-discovery efforts. For people with UC, it points to...

The study suggests molecular targets and pathways through which a traditional herbal formula might influence UC biology, offering testable hypotheses for future lab and clinical research.

Knowing which symptoms and non-invasive biomarkers most strongly associate with UC can help patients and clinicians decide who should be prioritized for diagnostic endoscopy and for monitoring disease activity.